WASHINGTON TRUST Co minimize its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 1.0% within the third quarter, HoldingsChannel reviews. The agency owned 126,690 shares of the corporate’s inventory after promoting 1,304 shares in the course of the quarter. WASHINGTON TRUST Co’s holdings in Johnson & Johnson had been value $20,531,000 as of its most up-to-date submitting with the Securities and Change Fee (SEC).
A number of different giant traders have additionally not too long ago made adjustments to their positions within the enterprise. Summit Wealth Companions LLC elevated its holdings in Johnson & Johnson by 0.6% within the 2nd quarter. Summit Wealth Companions LLC now owns 10,007 shares of the corporate’s inventory value $1,463,000 after buying a further 61 shares over the past quarter. Powers Advisory Group LLC elevated its holdings in Johnson & Johnson by 0.6% within the third quarter. Powers Advisory Group LLC now owns 9,489 shares of the corporate’s inventory value $1,538,000 after buying a further 61 shares over the past quarter. Residents & Northern Corp elevated its holdings in Johnson & Johnson by 3.5% within the 2nd quarter. Residents & Northern Corp now owns 1,884 shares of the corporate’s inventory value $275,000 after buying a further 63 shares over the past quarter. Eagle Wealth Methods LLC elevated its holdings in Johnson & Johnson by 2.8% within the third quarter. Eagle Wealth Methods LLC now owns 2,294 shares of the corporate’s inventory value $372,000 after buying a further 63 shares over the past quarter. Lastly, Epic Belief Funding Advisors LLC elevated its holdings in Johnson & Johnson by 3.6% within the 2nd quarter. Epic Belief Funding Advisors LLC now owns 1,831 shares of the corporate’s inventory value $268,000 after buying a further 64 shares over the past quarter. 69.55% of the inventory is owned by hedge funds and different institutional traders.
Johnson & Johnson Inventory Efficiency
Shares of JNJ opened at $159.86 on Friday. The corporate has a market cap of $384.88 billion, a PE ratio of 23.13, a price-to-earnings-growth ratio of two.90 and a beta of 0.52. The corporate has a present ratio of 1.07, a fast ratio of 0.85 and a debt-to-equity ratio of 0.44. The inventory has a 50-day shifting common worth of $163.39 and a 200-day shifting common worth of $155.35. Johnson & Johnson has a 12-month low of $143.13 and a 12-month excessive of $168.85.
Johnson & Johnson (NYSE:JNJ – Get Free Report) final issued its earnings outcomes on Tuesday, October fifteenth. The corporate reported $2.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.21. The enterprise had income of $22.47 billion in the course of the quarter, in comparison with analyst estimates of $22.17 billion. Johnson & Johnson had a return on fairness of 35.46% and a internet margin of 19.14%. Johnson & Johnson’s income for the quarter was up 5.2% on a year-over-year foundation. Throughout the identical quarter within the prior 12 months, the agency earned $2.66 earnings per share. As a gaggle, equities analysts forecast that Johnson & Johnson will publish 9.94 earnings per share for the present fiscal 12 months.
Johnson & Johnson Proclaims Dividend
The corporate additionally not too long ago introduced a quarterly dividend, which might be paid on Tuesday, December tenth. Shareholders of file on Tuesday, November twenty sixth might be paid a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of three.10%. The ex-dividend date of this dividend is Tuesday, November twenty sixth. Johnson & Johnson’s dividend payout ratio is at the moment 71.78%.
Insiders Place Their Bets
In different Johnson & Johnson information, VP Robert J. Decker bought 5,635 shares of the corporate’s inventory in a transaction that occurred on Friday, August thirtieth. The inventory was bought at a median worth of $165.06, for a complete worth of $930,113.10. Following the completion of the sale, the vice chairman now owns 18,973 shares of the corporate’s inventory, valued at $3,131,683.38. This represents a 0.00 % lower of their possession of the inventory. The sale was disclosed in a submitting with the Securities & Change Fee, which is on the market by way of the SEC web site. 0.16% of the inventory is owned by insiders.
Analysts Set New Worth Targets
JNJ has been the topic of a number of latest analysis reviews. Royal Financial institution of Canada lifted their worth goal on Johnson & Johnson from $178.00 to $181.00 and gave the inventory an “outperform” ranking in a report on Wednesday, October sixteenth. The Goldman Sachs Group decreased their worth goal on Johnson & Johnson from $160.00 to $155.00 and set a “impartial” ranking for the corporate in a report on Friday, July nineteenth. Cantor Fitzgerald restated an “chubby” ranking and issued a $215.00 goal worth on shares of Johnson & Johnson in a analysis word on Wednesday, October sixteenth. Morgan Stanley raised their goal worth on Johnson & Johnson from $169.00 to $175.00 and gave the inventory an “equal weight” ranking in a analysis word on Wednesday, October sixteenth. Lastly, Daiwa America downgraded Johnson & Johnson from a “strong-buy” ranking to a “maintain” ranking in a analysis word on Tuesday, July twenty third. Six analysis analysts have rated the inventory with a maintain ranking, seven have given a purchase ranking and one has given a robust purchase ranking to the corporate. Primarily based on knowledge from MarketBeat, Johnson & Johnson has a median ranking of “Reasonable Purchase” and a median goal worth of $175.93.
Learn Our Newest Evaluation on JNJ
About Johnson & Johnson
Johnson & Johnson, along with its subsidiaries, researches, develops, manufactures, and sells numerous merchandise within the healthcare area worldwide. The corporate’s Modern Medication section provides merchandise for numerous therapeutic areas, comparable to immunology, together with rheumatoid arthritis, psoriatic arthritis, inflammatory bowel illness, and psoriasis; infectious illnesses comprising HIV/AIDS; neuroscience, consisting of temper problems, neurodegenerative problems, and schizophrenia; oncology, comparable to prostate most cancers, hematologic malignancies, lung most cancers, and bladder most cancers; cardiovascular and metabolism, together with thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension by way of retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
See Additionally
Wish to see what different hedge funds are holding JNJ? Go to HoldingsChannel.com to get the newest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Obtain Information & Rankings for Johnson & Johnson Day by day – Enter your e-mail handle under to obtain a concise every day abstract of the newest information and analysts’ rankings for Johnson & Johnson and associated firms with MarketBeat.com’s FREE every day e-mail publication.
